Lung Cancer
Volume 75, Issue 2 , Pages 141-145 , February 2012

PET scans in radiotherapy planning of lung cancer

  • Dirk De Ruysscher

      Affiliations

    • Radiation Oncologist, Maastricht University Medical Center, Department of Radiation Oncology (MAASTRO Clinic), GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands
    • Corresponding Author InformationCorresponding author. Tel.: +31 884455666; fax: +31 884455773.
    • ,
  • Ursula Nestle

      Affiliations

    • Radition Oncologist and Nuclear Medicine Specialist, Department for Radiation Oncology, University Hospital, Freiburg, Germany
    • ,
  • Robert Jeraj

      Affiliations

    • Physicist, University of Wisconsin, Departments of Medical Physics, Human Oncology, Radiology and Biomedical Engineering, Madison, WI, USA
    • ,
  • Michael MacManus

      Affiliations

    • Radiation Oncologist, Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia

Received 13 June 2011 ,Accepted 25 July 2011.

References 

  1. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging. 2008;35:2320–2333
  2. Hellwig D, Baum RP, Kirsch C. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin. 2009;48:59–69
  3. Weber WA. Quantitative analysis of PET studies. Radiother Oncol. 2010;96:308–310
  4. Sattler B, Lee JA, Lonsdale M, et al. PET/CT (and CT) instrumentation, image reconstruction and data transfer for radiotherapy planning. Radiother Oncol. 2010;96:288–297
  5. Dooms C, Verbeken E, Stroobants S, et al. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography. J Clin Oncol. 2008;26:1128–1134
  6. De Ruysscher D, Faivre-Finn C, Nestle U, et al. European Organization for Research and Treatment of Cancer (EORTC) recommendations for planning and delivery of high-dose, high precision radiotherapy for lung cancer. J Clin Oncol. 2010;28(November):5301–5310[Epub ahead of print]
  7. Nestle U, Kremp S, Grosu AL. Practical integration of [18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol. 2006;81:209–225
  8. Nestle U, Schaefer-Schuler A, Kremp S, et al. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:453–462
  9. van Der Wel A, Nijsten S, Hochstenbag M, et al. Increased therapeutic ratio by 18FDG-PET-CT planning in patients with clinical CT stage N2/N3 M0 non-small cell lung cancer (NSCLC): a modelling study. Int J Radiat Oncol Biol Phys. 2005;61:648–654
  10. De Ruysscher D, Wanders S, Minken A, et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: results of a prospective study. Radiother Oncol. 2005;77:5–10
  11. De Ruysscher D, Wanders S, van Haren E, et al. Selective mediastinal node irradiation on basis of the FDG-PET scan in patients with non-small cell lung cancer: a prospective clinical study. Int J Radiat Oncol Biol Phys. 2005;62:988–994
  12. Belderbos JS, Heemsbergen WD, De Jaeger K, et al. Final results of a phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:126–134
  13. Sura S, Greco C, Gelblum D, et al. (18)F-fluorodeoxyglucose positron emission tomography-based assessment of local failure patterns in non-small-cell lung cancer treated with definitive radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:1397–1402
  14. Erdi YE, Mawlawi O, Larson SM, et al. Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding. Cancer. 1997;80(12 Suppl):2505–2509
  15. Nestle U, Kremp S, Schaefer-Schuler A, et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-small cell lung cancer. J Nucl Med. 2005;46:1342–1348
  16. van Baardwijk A, Bosmans G, Boersma L, et al. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys. 2007;68:771–778
  17. Stroom J, Blaauwgeers H, van Baardwijk A, et al. Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors. Int J Radiat Oncol Biol Phys. 2007;69:267–275
  18. Nestle U, Walter K, Schmidt S, et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys. 1999;44:593–597
  19. Schaefer A, Kremp S, Hellwig D, et al. A contrast-oriented algorithm for FDG-PET-based delineation of tumour volumes for the radiotherapy of lung cancer: derivation from phantom measurements and validation in patient data. Eur J Nucl Med Mol Imaging. 2008;35:1989–1999
  20. Lee JA. Segmentation of positron emission tomography images: some recommendations for target delineation in radiation oncology. Radiother Oncol. 2010;96:302–307
  21. Bayne M, Hicks RJ, Everitt S, et al. Reproducibility of intelligent contouring o gross tumor volume in non-small-cell lung cancer on PET/CT images using a standardized visual method. Int J Radiat Oncol Biol Phys. 2010;77:1151–1157
  22. Grgic A, Nestle U, Schaefer-Schuler A, et al. FDG-PET-based radiotherapy planning in lung cancer: optimum breathing protocol and patient positioning – an intraindividual comparison. Int J Radiat Oncol Biol Phys. 2009;73:103–111
  23. Nehmeh SA, Erdi YE, Rosenzweig KE, et al. Reduction of respiratory motion artifacts in PET imaging of lung cancer by respiratory correlated dynamic PET: methodology and comparison with respiratory gated PET. J Nucl Med. 2003;44:1644–1648
  24. Mac Manus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer. 2001;92:886–895
  25. Kolodziejczyk M, Kepka L, Dziuk M, et al. Impact of [(18)F]Fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2011;80:1008–1014
  26. Mac Manus MP, Wong K, Hicks RJ, et al. Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys. 2002;52:351–361
  27. van Baardwijk A, Wanders S, Boersma L, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stage I–III non-small cell lung cancer. J Clin Oncol. 2010;28:1380–1386
  28. Aerts HJ, Bosmans G, van Baardwijk AA, et al. Stability of (18)F-deoxyglucose uptake locations within tumor during radiotherapy for NSCLC: a prospective study. Int J Radiat Oncol Biol Phys. 2008;71:1402–1407
  29. Aerts HJ, van Baardwijk AA, Petit SF, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol. 2009;91:386–392
  30. van Baardwijk A, Bosmans G, Dekker A, et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy in relation to metabolic response. A prospective study in locally advanced non-small cell lung cancer patients. Radiother Oncol. 2007;82:145–152
  31. MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006–2007. Radiother Oncol. 2009;91:85–94
  32. Everitt S, Hicks RJ, Ball D, et al. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;75(November (4)):1098–1104
  33. Brink I, Schumacher T, Mix M, et al. Impact of [18F]FDG-PET on the primary staging of small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2004;31:1614–1620
  34. Fischer BM, Mortensen J, Langer SW, et al. A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Ann Oncol. 2007;18:338–345
  35. Niho S, Fujii H, Murakami K, et al. Detection of unsuspected distant metastases and/or regional nodes by FDG-PET in LD-SCLC scan in apparent limited-disease small-cell lung cancer. Lung Cancer. 2007;57:328–333
  36. Pandit N, Gonen M, Krug L, et al. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging. 2003;30:78–84
  37. Shen YY, Shiau YC, Wang JJ, et al. Whole-body 18F-2-deoxyglucose positron emission tomography in primary staging small cell lung cancer. Anticancer Res. 2002;22:1257–1264
  38. Kamel EM, Zwahlen D, Wyss MT, et al. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med. 2003;44:1911–1917
  39. De Ruysscher D, Bremer RH, Koppe F, et al. Omission of elective node irradiation on basis of CT-scans in patients with limited disease small cell lung cancer: a phase II trial. Radiother Oncol. 2006;80:307–312
  40. van Loon J, De Ruysscher D, Wanders R, et al. Selective nodal irradiation on basis of 18FDG-PET scans in limited disease small cell lung cancer: a phase II trial. Int J Radiat Oncol Biol Phys. 2010;77:329–336
  41. van Loon J, Offermann C, Bosmans G, et al. (18)FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: a planning study. Radiother Oncol. 2008;87:49–54
  42. Everitt S, Herschtal A, Callahan J, et al. High rates of tumor growth and disease progression detected on serial pretreatment fluorodeoxyglucose-positron emission tomography/computed tomography scans in radical radiotherapy candidates with nonsmall cell lung cancer. Cancer. 2010;116:5030–5037

PII: S0169-5002(11)00421-1

doi: 10.1016/j.lungcan.2011.07.018

Lung Cancer
Volume 75, Issue 2 , Pages 141-145 , February 2012

Article Tools

* Image Usage & Resolution